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Hypertension and Myocardial Infarction
FRANCIS G. DUNN, MB, ChB, FACC
Nell' Orleans . Louisiana
Because hypertension and myocardial infarction are
closely linked in several ways, a better understanding of
this relation leads to more effective prophylaxis and
management. Management should be directed at three
different areas: 1) the prevention of a first myocardial
infarction, 2) the prevention of complications after an
infarction, and 3) the management of hypertension dur-
An appreciation of the association between myocardial in-
farction and hypertension extends back for at least 40 years.
In 1940 , Sir Thomas Lewis wrote, " Thrombosis of a cor-
onary vessel is an accident occurring chiefly in men in their
fifties or sixties: it happens occasionally in women; it is rare
before the age of forty. The subjects usually present signs
of arterial disease and more often as not high blood pres-
sure" (I). More recently, evidence has confirmed that this
association is not simply one of risk factor and disease
because pathophysiologic and hemodynamic factors also
participate. This article focuses on the different ways in
which hypertension and myocardial infarction are linked
(Fig. I) and on management of systemic hypertension in
the context of an acute or a previous myocardial infarction.
The Link Between Hypertension and
Myocardial Infarction
Risk factor. Both systolic and diastolic hypertension
increase the risk of a myocardial infarction (2,3) and the
higher the pressure , the greater the risk (2). Even when
other major risk factors are absent, the increased risk still
exists (2,3). Almost 40% of patients with ischemic heart
disease who die suddenly have a history of hypertension
(4). The immediate and long-term mortality after infarction
in patients with hypertension is increased. This is likely to
be due at least in part to the frequency of complications
such as cardiac rupture and ventricular septal defect (5).
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ing evolution of an acute infarction. There is good evi-
dence that beta-receptor blocking agents are beneficial
to long-term management. When therapy is required in
the acute situation, arteriolar vasodilators are to be
avoidedand combinedarteriolar/venular dilators are the
drugs of choice.
The potency of hypertension as a risk factor is not uniform
throughout the world. For example, the black people in
southern Africa, despite a similar incidence of hypertension
and hypertensive heart disease, have a very small incidence
of myocardial infarction, presumably in part because of a
low serum cholesterol level (6) .
Because blood pressure is fr equently altered after acute
myocardial infarction. the patient's risk status is immedi-
ately altered. Kannel et al. (7) provided important infor-
mation on this subject. Thus, myocardial infarction in men
is accompanied by an average sustained decrease in systolic
pressure of 10.1 mm Hg. Of patients who were hypertensive
before the myocardial infarction , 40% had normalization of
pressure and 18% manifested a reversion from sustained to
borderline hypertension . The higher the initial pressure , the
more likely it was to decrease; those who experienced a
decrease were at a greater risk of heart failure. When patients
with decreases of 10 mm Hg were excluded, blood pressure
status after infarction continued to be related to mortality.
In view of these findings, it is clear that a reappraisal of the
individual patient' s hypertensive status is needed after an
acute myocardial infarction. Therapy is indicated for those
who remain hypertensive, and the same goals should be set
for this group as for other patients with hypertension.
Atherogenic factor. The term " myocardial infarction"
signifies a pathologic entity and says nothing of the mech-
anisms producing the infarct (although a previous commonly
used term "coronary thrombosis" implied both mechanism
and pathologic entity). There arc, of course, several ways
in which myocardial necrosis can occur, including coronary
artery spasm, coronary embolism, coronary artery dissection
and a variety of different myocardial toxins . Nonetheless,
by far the most common cause is atherosclerotic coronary
artery disease, and whether the precipitating event is throm-
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Figure I. The links between hypertension and myocardial mfarction (MI).
t BP = elevated blood pressure
bosis, spasm or plaque rupture, atheroma is the pathologic
hallmark in most cases of myocardial infarction.
There is good evidence from different sources pointing
to the role of hypertension in accelerating if not initiating
atherosclerosis. A greater percent of the intimal surface of
the aorta, coronary artery and cerebral artery is affected by
raised lesions in hypertensive persons than in normotensive
persons (8). The prevalence of coronary occlusive lesions
is also more common in patients with hypertension (8).
Pulmonary artery atherosclerosis is extremly rare except in
the presence of pulmonary hypertension (9). Many years
ago, Burch and dePasquale (10) reported a fascinating case
in which an anomalous left coronary artery (arising from
the pulmonary circulation) had virtually no atheroma, whereas
the normally arising right coronary artery showed much
more atherosclerotic change. An autopsy analysis of chil-
dren with nephrotic syndrome and hypercholesterolemia has
demonstrated coronary artery changes only in those children
also having an elevated blood pressure (II).
Studies in both animals and human beings have empha-
sized the importance of cholesterol in hypertension-accel-
erated atherosclerosis. and it appears that in the presence
of a low cholesterol level, the atherosclerotic potential of
hypertension is lessened (6). In addition to the mechanical
stress on the vessels, vasoactive substances may playa role
in the development of atherosclerosis. Norepinephrine has
been reported to produce atherosclerosis in rabbits (12), and
angiotensin (13) and prostaglandin (14) have been known
to increase vascular permeability. However, the role of
vasoactive substances remains conjectural at the present time.
Hemodynamic factors and effects on left ventricular
function. It is now well established that the hemodynamic
characteristics of essential hypertension are not homoge-
neous. Thus, early in the development of hypertensive vas-
cular disease, cardiac output may be elevated (15). How-
ever, with advancing vascular disease, progressively
increasing total peripheral resistance and developing left
ventricular hypertrophy, cardiac output will start to decrease
and left ventricular function will deteriorate (15,16). In ad-
dition, both hypertension and left ventricular hypertrophy
have important effects on myocardial perfusion. Systolic
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intraventricular pressure is a key determinant of myocardial
oxygen consumption (17) and therefore myocardial oxygen
demand will progressively increase as systolic pressure in-
creases. Furthermore, left ventricular hypertrophy is known
to be associated with a variety of factors that could adversely
affect the response to coronary occlusion. These include a
decrease in capillary density (18), a failure of vasodilator
capacity to increase in parallel with muscle mass (19), an
increase in coronary collateral resistance (20), more severe
subendocardial involvement and larger ischemic zones (20).
Thus. myocardial perfusion and ventricular function ab-
normalities occur in hypertension, independent of those ab-
normalities known to occur in ischemic heart disease.
Hypertension occurring during myocardial infarc-
tion. There is sound evidence that hypertension can occur
de novo in the evolution of a myocardial infarction (21,22).
This can take the form of combined systolic and diastolic
hypertension (21) or isolated systolic hypertension (23). The
reported incidence rate varies considerably from less than
5% to 43% (21,23). No specific relation appears to exist
between the location of the infarct and the presence of hy-
pertension, but there does appear to be a relation to the
frequency of proximal left main stem coronary artery disease
(21). Several mechanisms have been suggested. The anxiety
caused by the pain could raise the blood pressure, although
it has been shown that elevation of blood pressure may
precede cardiac pain (24). High levels of circulating cate-
cholamines are a possible explanation and there is evidence
to support this (25). Another interesting postulate is that the
hypertension is caused through activation of a cardiogenic
reflex initiated perhaps by the release of serotonin from
platelet aggregation in the proximal left coronary circulation
(21). However, the exact mechanism of the increase in blood
pressure remains to be clarified.
Clinical Evaluation
A full discourse on the clinical assessment of the patient
with hypertension and myocardial infarction will not be
presented. However, several points merit emphasis. Be-
cause atherosclerotic changes in the coronary arteries in-
crease the likelihood of atheroma elsewhere, careful exclu-
sion of renal artery stenosis is indicated, particularly when
the hypertension is of recent onset. Hypokalemia, whether
due to diuretic therapy or to a primary adrenal disorder,
should be investigated and treated vigorously in view of the
danger of ventricular premature complexes, which may be
already increased as a result of ischemic heart disease. Pheo-
chromocytoma may be heralded by a malignant ventricular
arrhythmia, by myocardial infarction or even by sudden
death (26). In all patients who present with myocardial
infarction and hypertension. the diagnosis of pheochromo-
cytoma should be kept in mind and a particularly assiduous
search should be made for this entity in younger patients.
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HDFP = Hypertension Detection and Follow-up Program: VA = Veterans
Adrmmstranon
Table 1. Blood Pressure Control and Subsequent Myocardial
Infarction: Prospective Trials
Diagnosis. Because diagnosing acute myocardial in-
farction in patients with hypertension on electrocardio-
graphic grounds may be difficult because of the presence
of preexisting ST and T wave changes, greater reliance has
to be placed on the history, cardiac enzymes and rest myo-
cardial perfusion scans. Conversely, if a previous myo-
cardial infarction has altered electrical forces, this may greatly
reduce the ability of the electrocardiogram to aid in diagnosis
of left ventricular hypertrophy. A two-dimensional echo-
cardiogram will be needed to confirm the presense of left
ventricular hypertrophy. This modality is preferable to the
M-mode echogram which has known limitations in patients
with the segmental wall motion abnormalities seen in cor-
onary artery disease.
the beta-receptor blocking agents produced a specific pro-
tective effect, and later studies on the role of these drugs
in myocardial infarction support this hypothesis. However,
the study of Berglund et al. was retrospective and was not
designed to answer the question at issue.
Of the three major trials reported in the past 2//2 years,
only the Hypertension Detection and Follow-Up Program
Cooperative Group study (31) showed a reduction in myo-
cardial infarction with good blood pressure control (and
without beta-receptor blocking agents). Neither the Austra-
lian (32) nor the Norwegian (33) study, each placebo-con-
trolled, confirmed this benefit. In fact, the Norwegian study
showed a slight (nonsignificant) increase in the incidence
of myocardial infarction in the treatment group (Table 1).
What conclusions can be drawn from these studies? It
may be presumptuous to expect that modification of one
risk factor over a relatively short period of time (in com-
parison with the duration of development of atherosclerosis)
will produce clear-cut results. The approach to reducing
myocardial infarction in a community must of its nature be
on a multiple risk factor intervention basis. This should
include nonpharmacologic and, if necessary, pharmacologic
control of blood pressure. Because it is conceivable that
patients in the high risk group for myocardial infarction are
particularly sensitive to the biochemical adverse effects of
diuretic drugs (particularly hypokalemia), beta-receptor
blocking agents seem to be a more logical choice of step I
therapy (Fig. 2). The results of three recent postmyocardial
infarction trials have confirmed the benefit of beta-receptor
blocking agents in this context after both short-term (34)
and long-term (35,36) use. Although the calcium slow chan-
nel blocking agents (three of which have been recently in-
troduced in this country for the treatment of angina) offer
great potential in patients after a myocardial infarction, their
prophylactic value remains to be proved.
Hypertension and infarct size. There has been much
interest in recent years concerning the relation between myo-
cardial infarct size and oxygen requirements in acute myo-
cardial infarction (37). We know that reduction in myo-
cardial oxygen requirements can reduce the extent of
myocardial injury after coronary occlusion. Because systolic
pressure is a major determinant of myocardial oxygen con-
sumption and diastolic pressure has a critical relation to
coronary flow, it is clear that both hypertension and hy-
potension will induce important and possibly adverse hemo-
dynamic effects in acute myocardial infarction. In experi-
mental studies in dogs, the extent of the myocardial damage
was dependent on arterial pressure; hypertension reduced
myocardial injury and hypotension increased myocardial
injury (38). However, it has been shown that reducing blood
pressure in human subjects with acute myocardial infarction
and hypertension improved hemodynamics and decreased
infarct size (39). These discrepant results can be explained
by differences in collateral circulation between dogs and
o
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Management
Role of antihypertensive treatment in incidence of
myocardial infarction. Is treatment of hypertension effec-
tive in reducing the incidence of myocardial infarction?
Confusion in the published reports regarding this question
is understandable (Table I) when one considers that hy-
pertension is only one of many factors that predispose a
patient to infarction. Furthermore, clinical trials use clinical
end points for obvious reasons, and to date we have no
acceptable method of assessing whether risk factor modi-
fication affects the atherosclerotic process itself. The com-
position of the study population also influences results, and
even two symptom-free populations without clinical features
of ischemic heart disease may have widely varying degrees
of atherosclerosis. These points must be considered by those
interpreting the results of currently available trials.
Early prospective trials (27,28) did not reveal any sig-
nificant reduction in myocardial infarction in patients with
moderate and severe hypertension, although one retrospec-
tive analysis (29) did suggest a possible reduction in clinical
events. Berglund et al. (30) followed up a group of 1,026
hypertensive patients and found that those receiving beta-
receptor blocking agents showed a definite reduction in the
incidence of nonfatal infarction and death. It is possible that
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Figure 2. Alternative stepwise approaches to treatment of hypertension
in the patient after acute myocardial infarction. The regimen on the left
may be considered in patients with continuing symptoms of myocardial
ischemia. The regimen on the right may be considered when hypertension
persists. (These regimens are in addition to the use of nitrates.) B = beta;
SC = slow channel.
human beings. In the dog, collateral blood supply is highly
developed so that the deleterious effects of hypertension on
myocardial oxygen consumption are offset by increases in
collateral flow to ischemic areas. Patients do not have such
extensive collateral circulation and therefore the deleterious
effects of hypertension on increasing oxygen consumption
are not offset by increases in collateral flow to the ischemic
zones. Of course, there is wide individual variation among
patients in collateralization and in the optimal blood pressure
for adequate cardiac function. It is clear that no precise
optimal pressure level can be given. Nonetheless, certain
guidelines can assist in determining the approximate pres-
sure that would be most beneficial to the patient with an
acute myocardial infarction.
Guidelines for blood pressure reduction in acute myo-
cardial infarction. In most patients, acute hypertension
that occurs de novo in the evolution of an acute myocardial
infarction will resolve spontaneously within a period of hours.
Some workers (23) suggest that a systolic pressure of less
than 170 mm Hg should be treated; others (40) argue that
the acute increase in systolic pressure is transient and rarely
severe and may be supportive in terms of cerebral and renal
perfusion. Still others (21) have advocated that no treatment
be administered unless the pressure elevation is "severe"
or sustained beyond 24 hours. The temporary elevation does
not appear to have an adverse effect on the prognosis of
acute myocardial infarction. The following is my approach
to this difficult clinical problem.
Once the presence of persistent hypertension has been
established after pain is relieved, the patient's clinical and
hemodynamic status should be assessed. If there is evidence
of heart failure, appropriate therapy should be initiated to
reduce vascular resistance and ventricular filling pressure
(to approximately 15 mm Hg). Pure arteriolar dilators such
as hydralazine, minoxidil and diazoxide should not be used
because they reflexively increase heart rate and myocardial
contractility (and, therefore, myocardial oxygen consump-
tion and the ischemic area around the infarct) (Table 2).
Because nitroprusside and nitroglycerin, by virtue of their
venodilating properties, cause only minimal reflexive ef-
fects, they are the agents of choice in such circumstances.
Ifthe patient does not have heart failure, a less aggressive
approach can be taken; control of arterial pressure should
be individualized. Marked elevations of pressure should be
treated with nitroprusside or nitroglycerin, whereas less se-
vere pressure elevations can be monitored closely and treated
as warranted by the patient's clinical condition. This ap-
proach seems to be indicated until we know the optimal
perfusion pressure in the first stage of infarction and until
we assess the effect of treating moderate hypertension on
infarct size.
Oral antihypertensive agents should be used with caution
in the immediate postinfarction state because sudden re-
versal of a drug's hypotensive action may be needed and
this may not be easily accomplished with oral therapy. The
importance of careful hemodynamic monitoring and titration
of therapy cannot be overemphasized when reducing blood
pressure after an acute myocardial infarction.
Conclusion
Hypertension is linked to myocardial infarction as a risk
factor, an atherogenic factor and a hemodynamic factor. It
may also occur in the course of an acute myocardial in-
farction. Both these disorders have serious adverse cardiac
effects and both have profound effects on morbidity and
mortality. Although there have been conflicting results re-
garding reduction in the incidence of myocardial infarction
after treatment of hypertension, it is likely that future long-
term trends will show a reduced incidence with prolonged
control of blood pressure.
Treatment of hypertension in the context of an acute
myocardial infarction is a problematic area. Severe hyper-
tension and hypertension in the context of heart failure should
be treated with careful hemodynamic monitoring and an
appropriate choice of therapy. The development of cardio-
vascular drugs that are efficacious in both hypertension and
myocardial infarction represents a major advance in treat-
Table 2. Cardiac Effects of Parenteral Antihypertensive Agents
Heart Cardiac Myocardial Myocardial
Rate Output Contractility Ischemia
Nitroglycerin t t
Nitroprusside t t
Diazoxide t t t t t t t t t t t
Minoxidil t t t t t t t t t t i
Hydralazine t t t t t t t
i = slightly increased; i i = moderately increased. iii = greatly 10-
creased: - = unchanged.
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ment when these two disorders coexist and is likely to be
reflected in a reduced incidence of initial myocardial in-
farction and an improved prognosis after its occurrence.
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